Slingshot members are tracking this event:
Phase 1/2 clinical trial preliminary data of AMT-060 for hemophilia B due January 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jan 07, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 1/2, Amt-060, Hemophilia B